Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial
Alexios Matikas(Karolinska University Hospital), I. Thalmann, Stig Holmberg(Sahlgrenska University Hospital), Eva‐Maria Grischke(Universitair Ziekenhuis Leuven), Benjamin Schnappauf, Yvonne Brandberg(Karolinska Institutet), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Matthias Kögel, Thomas Göhler, G. W. Hoffmann, Maria Dietrich, A. Kohls, Richard Greil(Paracelsus Medical University), Gerold Baake, Gabriele Ziemendorff, Per Edlund(Gävle Hospital), Martin Söderberg, Johan Ahlgren(Uppsala University), Lena Carlsson(University of Gothenburg), Theodoros Foukakis(Karolinska Institutet), Barbro Linderholm(Karolinska University Hospital), Zakaria Einbeigi, Mats Hellström(Karolinska University Hospital), Henrik Lindman(Uppsala University), Tommy� Fornander(Karolinska University Hospital), Sabine Schmatloch, Jonas Bergh(Karolinska Institutet), Volker Möbus, Hemming Johansson(Karolinska Institutet), Anne Andersson(Umeå University), Elham Hedayati, Volker Heyl, Sibylle Loibl(Goethe University Frankfurt), Per Karlsson(University of Gothenburg), Ralf Adrion, Eva Karlsson, Niklas Lohman, Lotta Dabrosin, Per Malmström, Sam Rotstein, Nils‐Olof Bengtsson, Günther Steger(Barwon Health), Birgitta Wallberg, Kenneth Villman(Örebro University Hospital), Michael Untch(Helios Kliniken)
Cited by 11
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
|New England Journal of Medicine|2007|4.6k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k